Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/1999

01-03-1999 | SHORT COMMUNICATION

Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism

Authors: Dagmar Busse, Friedrich W. Busch, Eberhard Schweizer, Frank Bohnenstengel, Michel Eichelbaum, Peter Fischer, Kurt Schumacher, Walter E. Aulitzky, Heyo K. Kroemer

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/1999

Login to get access
Metadata
Title
Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism
Authors
Dagmar Busse
Friedrich W. Busch
Eberhard Schweizer
Frank Bohnenstengel
Michel Eichelbaum
Peter Fischer
Kurt Schumacher
Walter E. Aulitzky
Heyo K. Kroemer
Publication date
01-03-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050893

Other articles of this Issue 3/1999

Cancer Chemotherapy and Pharmacology 3/1999 Go to the issue

ORIGINAL ARTICLE

The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule

ORIGINAL ARTICLE

Antitumor activity, distribution, and metabolism of 13-cis -retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice

ORIGINAL ARTICLE

Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study

ORIGINAL ARTICLE

Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice

CLINICAL TRIAL REPORT

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

ORIGINAL ARTICLE

Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits